Scientists Identify Previously Unknown Lymphatic Drainage Route at the Back of the Eye

A Canadian research team has mapped a new lymphatic pathway draining fluid from the choroid, challenging a century-old assumption that the posterior eye has no lymphatic system and opening a fresh therapeutic target for glaucoma, macular degeneration and other posterior segment diseases.

For more than 100 years, ophthalmology has operated on the assumption that the eye, unlike almost every other organ in the body, has no lymphatic system to clear waste and regulate fluid. A new study out of the University of British Columbia and the University of Toronto suggests that assumption needs revising at least for the back of the eye.

Published this month in Translational Vision Science & Technology, the study identifies what the researchers have named the posterior ocular lymphatic outflow, or POLO, pathway: a route by which fluid and waste exit the choroid via lymphatic vessels and ultimately reach the body's broader lymphatic network.

What the researchers found

Using a mouse model, the team led by Dr Neeru Gupta (head of UBC's Department of Ophthalmology and Visual Sciences) and Dr Yeni Yücel (director of ophthalmic pathology at the University of Toronto) injected albumin-based fluorescent and MRI tracers into the suprachoroidal space and tracked their movement using MRI, near-infrared fluorescence imaging and confocal microscopy.

The tracers consistently drained toward the nasal orbit and, within 20 minutes, reached the ipsilateral accessory submandibular cervical lymph node the same side as the injected eye, with no signal detected on the untreated side. Tissue analysis confirmed the tracer's path passed through vessels expressing podoplanin, VEGFR-3 and Prox1, three markers used to positively identify lymphatic, rather than blood, vessels, distinguishing them clearly from the surrounding choroidal vasculature.

Notably, suprachoroidal injection did not produce any measurable change in intraocular pressure compared with vehicle controls, suggesting the drainage observed reflects a genuine physiological pathway rather than an artefact of the injection itself.

Why it matters for the clinic

The choroid sits directly behind the retina, one of the most metabolically demanding tissues in the body, and diseases rooted there; glaucoma, age-related macular degeneration, uveitis, exudative retinal detachment and uveal effusion syndrome among them; are all characterised by impaired clearance of fluid, protein and inflammatory debris.

"The retina is one of the most metabolically active parts of the body, constantly generating byproducts that need to be cleared," Dr Gupta said. "This discovery helps explain how the eye flushes this waste and promises to transform how we think about and treat a range of eye conditions."

Age-related macular degeneration alone affects an estimated 2.5 million Canadians, and the researchers note similar prevalence pressures apply globally. A functional clearance pathway at the back of the eye gives clinicians and researchers a new physiological target, not just for managing intraocular pressure, but potentially for improving drug delivery to posterior segment tissue and developing therapies that enhance fluid clearance directly.

Building on earlier work

The POLO pathway builds on research Gupta and Yücel began in 2009, when they first identified a lymphatic-related drainage route at the front of the eye, the "uveolymphatic" pathway, through the ciliary body. That anterior pathway has since been shown to respond to existing glaucoma medications, with latanoprost enhancing lymphatic drainage and timolol reducing it, and to decline with age.

Whether the newly identified posterior pathway shares that pharmacological responsiveness, and whether it exists and functions the same way in the human eye, remains to be established. The authors are explicit that this study offers discrete time-point imaging rather than continuous flow measurement, and that vessel-level continuity along the full route has not yet been confirmed.

What's next

The team says future work will need time-resolved, quantitative imaging techniques such as multispectral photoacoustic tomography, tracers of varying molecular size, and selective lymphatic blockade in genetic models to better characterise the pathway's kinetics and pharmacology and, eventually, translational studies to confirm the pathway's presence and behaviour in humans.

"This is a foundational discovery that shows the eye is not as closed a system as we previously thought," Dr Gupta said. "It gives us a new map, a new mechanism and a new set of questions to explore."